Data to describe our patient population will be collected at baseline and will include demographic and clinical data.
Demographic data will be collected at baseline and will include age, gender, height, weight, country of birth, education, source of income, falls history, eye problems, health conditions, medications, walking aids, use of community services, foot problems, foot posture and use of podiatry services.
Static lung volumes measured via plethysmography will be measured at baseline only and will include total lung capacity (TLC), functional residual capacity (FRC) and residual volume (RV).
This visit will be planned for at least six months after the original baseline visit and will include the reassessment of asthma symptoms, medication use, adherence to ICS and levels of FeNO.
Analyses of secondary (effectiveness) outcomes will be by mixed models, which allow for repeated measures (baseline and follow-up) and will include all participants with baseline data (including those with missing data at follow-up) with adjustment for predictors of dropouts to minimise non-response bias.
Baseline data will include patient demographics and their existing comorbidities, medical and surgical history, medications, allergies and social history including smoking, alcohol and drug use.
Baseline assessment will include demographic variables and data for the duration of the gambling problem.
Baseline measurements will include lifestyle measurements, anthropometric characteristics and a comprehensive cardiovascular examination.
The baseline factors will include age, sex, medication status, psychological and lifestyle characteristics.
The baseline assessment will include age, socio-demographic data, smoking and alcohol use, medical conditions, history of candidiasis, history of prior pregnancies including preterm birth, gestational age at enrolment and method of gestational age assessment (ultrasound or dates).
